Thinking straight about orphan drugs, Part 5.
In my last post, I canvassed two common ways that manufacturers game the Orphan Drug Act. Today I’ll cover the third—“salami slicing.” Many common diseases
In my last post, I canvassed two common ways that manufacturers game the Orphan Drug Act. Today I’ll cover the third—“salami slicing.” Many common diseases
Medicare Beneficiaries Face Growing Out-Of-Pocket Burden For Specialty Drugs While In Catastrophic Coverage Phase, Health Affairs Part D Generic Drug Prices Declined Overall, but Some Had Extraordinary Price Increases,
the health services research blog
Work posted here under copyright © of the authors • Details on the Site Policies page